Mylan Pharmaceuticals ULC

What Mylan Pharmaceuticals ULC does

Mylan Pharmaceuticals ULC is a Canadian pharmaceutical company operating as the regional Canadian subsidiary of Viatris Inc., a publicly traded global healthcare company. The entity is domiciled in Canada as an Unlimited Liability Company (ULC) and markets a portfolio of 108 registered products across 291 Stock Keeping Units (SKUs), spanning both branded specialty and generic pharmaceutical categories. Its flagship product is Synthroid, a thyroid hormone replacement medication with 120.89+ million prescriptions recorded in Canada as of February 2024 per IQVIA data. The company distributes products through pharmacy retail channels and direct engagement with healthcare provider networks across Canada.

The underlying technology base is pharmaceutical manufacturing and drug formulation, with no proprietary AI, software platform, or digital product layer disclosed. The company's go-to-market motion operates through wholesale and retail pharmacy distribution, supplemented by direct sales to healthcare providers for specialty and branded products. Revenue is generated through one-time license sales of pharmaceutical products (branded and generic prescription medicines plus over-the-counter treatments) distributed via pharmacy and healthcare channels. Pricing is not publicly disclosed and is subject to regulatory approval and market-specific negotiations.

As a wholly-owned subsidiary of Viatris Inc. — formed through the 2020 combination of Mylan N.V. and Pfizer's Upjohn division — Mylan Pharmaceuticals ULC benefits from integration into a global pharmaceutical company operating across more than 40 countries. The Canadian subsidiary employs 158 people in Canada and contributes to a global production capacity exceeding 1.45 billion doses. Its customer base is segmented horizontally across Patients/Healthcare Consumers and Healthcare Providers, with no named enterprise customer logos disclosed and no selective customer list available.

Name

Mylan Pharmaceuticals ULC

Legal name

Mylan Pharmaceuticals ULC

Website

https://mylan.ca

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

Mylan Pharmaceuticals ULC is the Canadian pharmaceutical subsidiary of Viatris Inc., distributing 108 registered generic and branded prescription medicines across 291 SKUs through pharmacy and healthcare provider channels in Canada, anchored by Synthroid.

Ownership category

akta.pro rank

Headquarters

HQ city

Canada

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of branded and generic pharmaceutical products including prescription medicines and over-the-counter treatments distributed through pharmacy and healthcare channels.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Mylan Pharmaceuticals ULC, operating as Viatris Canada, manufactures and distributes a broad portfolio of generic and branded pharmaceutical medicines in Canada. The company markets 108 registered products across 291 Stock Keeping Units (SKUs), spanning therapeutic areas and including heritage brands such as Synthroid (a thyroid hormone replacement medication). Products are distributed through pharmacy retailers, wholesale channels, and direct healthcare provider networks across Canada.

Product overview

Mylan Pharmaceuticals ULC, operating as Viatris Canada, offers a broad portfolio of high-quality generic and branded pharmaceutical medicines. The company markets 108 registered products across 291 Stock Keeping Units (SKUs), including well-known brands such as Synthroid (a thyroid medication). Products are organized under categories including Branded Specialty and a comprehensive Product Catalogue. The company focuses on ensuring patient access to essential treatments across various therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Synthroid Thyroid hormone replacement medication; a major prescription brand product with over 120.89 million prescriptions recorded as of February 2024 (IQVIA, CDH CompuScript, MAT 02/2024).

Quantifiable outcome

• 1.45+ billion doses delivered to patients globally
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Teva Canada: Teva Canada is the Canadian arm of Teva Pharmaceutical Industries, a global generic and specialty pharma leader that competes head-to-head with Mylan/Viatris in generics distribution, retail pharmacy channels, and specialty therapeutic categories across Canada.
• Pharmascience Inc. Pharmascience is a privately held Canadian pharmaceutical manufacturer offering branded generics, OTC, and consumer health products through the same retail pharmacy and wholesale channels as Mylan Pharmaceuticals ULC, with comparable headcount and Canadian market focus.
• Apotex Inc. Apotex is Canada's largest generic pharmaceutical manufacturer, directly competing with Mylan Pharmaceuticals ULC across prescription generics, OTC products, and active pharmaceutical ingredients distributed through the same pharmacy and wholesale channels in Canada.
• Sandoz Canada: Sandoz Canada, the generics division of Novartis, directly competes with Mylan Pharmaceuticals ULC across generic finished dosage forms and biosimilars distributed through Canadian pharmacy and hospital channels, with comparable portfolio breadth and pricing models.

Broad incumbents

• AstraZeneca Canada Inc. AstraZeneca Canada is the Canadian subsidiary of AstraZeneca plc, a multinational pharmaceutical incumbent. It operates in overlapping therapeutic categories (cardiovascular, respiratory, oncology) with comparable specialty and primary care distribution through Canadian pharmacy channels.
• Pfizer Canada ULC: Pfizer Canada is the Canadian subsidiary of Pfizer Inc., a broad incumbent offering innovative specialty pharmaceuticals, vaccines, and consumer health products. It overlaps with Mylan's branded specialty portfolio and shares corporate lineage, as Pfizer's Upjohn division combined with Mylan to form Viatris.
• Merck Canada Inc. Merck Canada, the Canadian arm of Merck & Co., is a broad pharmaceutical incumbent offering innovative specialty and primary care medicines distributed through the same pharmacy retail and healthcare provider channels that Mylan Pharmaceuticals ULC relies upon.
• Sanofi Canada: Sanofi Canada is the Canadian subsidiary of Sanofi S.A., a multinational pharmaceutical incumbent offering branded specialty, generics, and consumer health products through comparable distribution channels, with overlap in chronic disease and specialty therapeutic categories served by Mylan Pharmaceuticals ULC.
• Novartis Pharmaceuticals Canada Inc. Novartis Canada operates as a broad pharmaceutical incumbent offering innovative specialty medicines. Through its Sandoz division it directly competes in generics, and overall Novartis competes with Mylan Pharmaceuticals ULC in therapeutic areas where both maintain branded specialty presence.

Emerging players

• Biosyent Inc. Biosyent is a Canadian specialty pharmaceutical company focused on branded and licensed products for the Canadian market. It represents an emerging player with narrower portfolio focus but overlapping distribution channels and therapeutic areas where Mylan Pharmaceuticals ULC competes.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Customer concentration

• YouTubeyoutube.com/channel/UCWVqREHI9o39CMlIzqczAag
• LinkedInlinkedin.com/company/mylan-pharmaceuticals-ulc
• Instagraminstagram.com/viatrisinc
• Xx.com/viatrisinc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mylan Pharmaceuticals ULC